Ten one-pagers. Ten tailwinds.

The business

• Incorporated in 1978; pivoted to solar in 2009 after a journey through jute trading, IT peripherals (the 'Frontech' brand) and optical media. Today a near pure-play solar manufacturer.
• Operates an integrated cell facility at Baddi, Himachal Pradesh (~0.96 GW), producing high-efficiency Mono PERC cells with peak efficiency ~23.4%. Expanding into modules and integrated cell-module units, with technology partnerships in Germany and Egypt.
• Revenue model: large-volume cell supply and long-term contracts with module makers (Tata Power Solar, Waaree, Webel Solar). Capacity guided to scale toward 6.4 GW cells / 2.4 GW modules via a new Khorda, Odisha hub.

The catalyst

• Structural domestic-manufacturing push: high Basic Customs Duty on imported cells, ALMM listing requirements and PLI incentives improve cost competitiveness versus Chinese imports.
• Demand drivers: PM Surya Ghar, PM-KUSUM, CPSU and rooftop programs underpin multi-year domestic solar demand. Global solar market estimated to compound at 20%+.
• Margin tailwind from shift to higher-value Mono PERC / TOPCon and increasing integration across cell-module.

The financials

The standout is margins, not topline. FY25 revenue actually dipped slightly to ₹556 cr (from ₹578 cr), but EBITDA nearly doubled to ₹226 cr and OPM jumped to ~40.7% (from ~20%) on a richer Mono PERC mix and lower input costs, taking PAT to ₹123 cr. FY23 was a loss year (₹36 cr) during the transition. Source: UnlistedZone P&L. EPS shown pre the later split/bonus. (Note: market-cap and per-share ratios in the box below are on the current, post-split/bonus ~74.5 cr share base.)

The backers

• Promoter Alok Garodia; 30+ years of group manufacturing experience.
• Institutional backing from ValueQuest (~Rs 300 cr via S.C.A.L.E. Fund) and Edelweiss Alternatives supporting the scale-up.
• Proposed total fundraise of ~Rs 800 cr (Rs 600 cr equity + Rs 200 cr) to fund the 2.4 GW Odisha cell expansion.

The valuation

• On FY25 PAT of ₹123 cr the headline P/E is ~140x — optically expensive. But the FY25 story is the margin inflection (OPM ~20% → ~41%), and the real driver is the capacity build-out to 6.4 GW cells / 2.4 GW modules by FY27.
• If the new GW come online and margins hold, FY26 and FY27 earnings can rise sharply from the ₹123 cr base — which would collapse the forward P/E even if the price stays put. The thesis is execution on capacity and sustained margins, not today's trailing multiple.
• The flip side: a single dip in cell prices or a margin give-back (FY25's ~41% OPM is high for the industry and may normalise), plus a slip in the expansion, would leave a rich multiple exposed.

The business

• Listed parent of PPFAS Asset Management, sponsor of PPFAS Mutual Fund. Founded by the late Parag Parikh (1992); the AMC was set up in 2012-13 after the brokerage was wound down.
• Runs a small, focused set of schemes - Flexi Cap (flagship), ELSS, Liquid, Conservative Hybrid, Arbitrage, Dynamic Asset Allocation and Large Cap - charging an expense ratio, a slice of which (the management fee) flows to the AMC.
• 'Skin in the game' culture: employees and the AMC invest alongside unit-holders. Heavy tilt to equity AUM, which earns higher fees.

The catalyst

• Strong operating leverage: as AUM grows, fixed costs stay broadly stable, so incremental revenue is highly profitable.
• AUM scaled from ~Rs 1,961 cr (2019) to ~Rs 1.06 lakh cr (Mar-2025) and well over Rs 1.3 lakh cr by Sep-2025; the Flexi Cap Fund crossed Rs 1 lakh cr, the largest actively-managed equity flexi-cap in India.
• Investor base grew from ~80,000 (2019) to ~49 lakh; broad structural growth in Indian mutual-fund penetration and SIP flows.

The financials

Revenue nearly doubled in FY25 as equity AUM compounded. AUM in ₹ cr; FY23/FY24 splits are indicative. The model's operating leverage shows up in the steady ~57–59% PAT margin even as the base scales.

The backers

• Led by Neil Parikh (Chairman & CEO), continuing the founder's behavioural-finance, long-term value philosophy.
• Rajeev Thakkar - the star fund manager - is CIO and the public face of the investment process, managing the flagship Flexi Cap Fund since inception (2013). His disciplined, valuation-conscious, behavioural-finance approach and willingness to hold cash or overseas equities when ideas are scarce have built a strong long-term track record and much of the fund's credibility.
• Reputation for ethical, research-driven, conviction-led investing - a key intangible asset for a boutique AMC.

The valuation

• Re-rated hard — unlisted price ~₹5,400 (Oct-24) to ~₹17,500 (Sep-25). At ~10% Mcap/AUM it sits between Nippon and HDFC AMC; cheaper than HDFC on P/E despite faster growth.
• Not 'cheap' in absolute terms — the multiple already prices in continued AUM compounding, so the margin for disappointment is thin.

The business

• Incorporated Aug-2023 as a subsidiary of Goodluck India to manufacture specialised forgings and precision-engineered components for defence and aerospace.
• Dedicated facility at Sikandrabad, Uttar Pradesh (forging, machining, heat treatment, surface coating). Flagship product: 155 mm artillery shells (24-32 km range) plus HE, precision-guided, armour-piercing, smoke and illumination variants.
• The 1,50,000 shells/year capacity is now LIVE and export orders have started. FY26-FY27 is the first full revenue year. Capacity is being expanded further toward ~4 lakh shells/year.

The catalyst

• Global artillery-shell shortage: the Russia-Ukraine war drained stockpiles, and Europe in particular has strong, sustained demand to rebuild inventories - so demand should stay elevated for years, not quarters.
• India's defence indigenisation, rising defence capex and export ambitions add a second, domestic demand leg.
• Rare industrial licence under the Arms Act to make artillery shells across all five major calibres (105-155 mm) - a durable entry barrier - plus parent Goodluck India's 39-year forging pedigree and relationships (DRDO, HAL, ISRO, BrahMos, L&T Defence).

The financials

GDAL was incorporated Aug-2023, so there is no meaningful 3-year revenue history yet. The 1,50,000 shells/year line is now LIVE and export orders have started — FY26–FY27 is the first full revenue year, with capacity being expanded toward 4 lakh shells/year.

The backers

• Backed and ~81% owned by parent Goodluck India, providing capital, infrastructure and certifications.
• Raised ~Rs 136.5 cr; post-money valuation cited around Rs 764 cr at the funding stage.
• Export tie-ups under exploration with global majors (e.g., Nexter, Rosoboronexport, Elbit).

The valuation

• Goodluck India's concall guides to ~₹1,000 cr defence revenue by FY30, with the 4-lakh-shell capacity targeted live around FY28.
• Back-of-envelope at full capacity: 4 lakh shells × ~₹26,000 avg price ≈ ₹1,000 cr revenue; at 30–35% EBITDA and ~15% PAT margin that's ~₹150 cr PAT. On a 40x P/E that implies a ~₹6,000 cr market cap — versus ~₹1,800 cr today.
• That re-rating depends on capacity utilisation and sustained order flow, but the plant and early export orders de-risk the 'will it ever produce' question.

The business

• Incorporated 2018 (formerly Pranurja Solutions); operational since Jul-2022. One of only three CERC-approved power exchanges alongside IEX (90%+ share) and PXIL.
• Operates an electronic platform for electricity trading: Day-Ahead (DAM), Term-Ahead (TAM), Intra-Day (IDM), Real-Time (RTM), Green DAM, contingency and Renewable Energy Certificates.
• Exchange economics: high operating leverage - once platform infrastructure is built, incremental trades drop largely to profit. Net cash-flow positive (~Rs 143 cr in FY24 per one source); capital-light, scalable model.

The catalyst

• Market coupling: the central reform that would pool bids across exchanges and allocate volume by a common clearing price - widely expected to redistribute share toward newer venues like HPX. Management has guided for a large share gain post-coupling.
• Structural growth in short-term power trading, open access, renewable integration and cross-border trade.
• Rapid early traction: traded 1 bn+ units within six months of launch; secured a meaningful slice of TAM within two years.

The financials

FY23 was the first operating year — ₹17.4 cr revenue with a ~₹10 cr loss on a high fixed-cost base. FY24 was the turnaround: ₹43.6 cr revenue, ₹14.9 cr PAT, ~41% net margin. In 9M FY26, income grew to ₹36.4 cr (vs ₹30.27 cr) but PAT slipped to ₹4.42 cr (from ₹8.38 cr) as HPX spends on technology and manpower ahead of market coupling. Source: PTC India Q3 FY26 earnings call (PTC holds ~22.5%).

The backers

• Promoted by PTC India (India's leading power trader), BSE Investments (exchange operations) and ICICI Bank (financial/clearing) - a strong, credible promoter trio.
• Governance and clearing strength from established institutional backers.

The valuation

• On trailing numbers the ~137x P/E and ~21x P/B look steep for a sub-₹50 cr revenue exchange that is currently in an investment phase (FY26 profit dipped on tech/manpower spend).
• The entire thesis is the option on market coupling: APTEL has directed that it be implemented across exchanges, which would pool volume and could hand HPX a much larger share (management has talked of 40–45% post-coupling). On this capital-light, high-operating-leverage model, incremental volume converts to profit fast.
• It remains an option, not a certainty — implementation waits on a formal CERC regulation, and the timeline is outside the company's control.

The business

• Founded 2004; provides engineered solutions, turnkey installations and high-end engineering across nuclear, defence, oil & gas and broader industrial segments. Multi-ISO certified.
• Verticals: Nuclear Engineering Solutions (regulatory documentation, waste management, decommissioning, fuel reprocessing support), Engineering & Turnkey Systems, and Industrial Engineering Services.
• Marquee client base across DAE units (NPCIL, BARC, IGCAR, UCIL), O&G PSUs (ONGC, HPCL, BPCL) and the armed forces - competes on technical capability and approvals rather than price.

The catalyst

• India's nuclear ambition: target of 100 GW nuclear capacity by 2047 (vs ~8.9 GW today), plus Small Modular Reactor (SMR) / Bharat Modular Reactor (BMR) programs under Atmanirbhar Bharat.
• Defence indigenisation and rising O&G / petrochemical capex broaden the opportunity set.
• High regulatory entry barriers (nuclear-grade approvals) create a durable moat for qualified players.

The financials

FY25 was a breakout year — revenue nearly doubled to ₹218 cr (from ~₹113 cr) and PAT jumped ~9x to ₹18.5 cr, with EPS at ₹75.82. The lumpiness is typical of project-driven EPC: FY23–FY24 were thin on profit before the order book converted. Source: UnlistedZone P&L.

The backers

• Two decades of niche execution track record and regulatory approvals.
• Ace investor Ashish Kacholia (the 'Big Whale') invested ~Rs 46 cr at Rs 7,260 per share - a notable marquee-investor validation of the nuclear-EPC thesis.
• Raised Rs 200 cr (FY24-25, ~Rs 199 cr across tranches); early AIF investor (via Maharashtra Defence & Aerospace Venture Fund) exited at the round, signalling institutional validation.

The valuation

• Marquee validation: ace investor Ashish Kacholia put in ~₹46 cr at ₹7,260/share. The unlisted price has since moved to ~₹17,400 — roughly 2.4x his entry — so newer buyers are paying well above the price a respected investor anchored at.
• On FY25 EPS of ~₹76 the trailing P/E is rich, but it follows a year where PAT jumped ~9x, so the multiple is being set off a fast-rising base.
• The moat (AERB approvals, ISO 19443, two decades of NPCIL/BARC work) is real, but EPC revenue is lumpy and disclosure is limited — and the price has already run hard past the marquee entry, so size positions accordingly.

The business

• Incorporated Jun-2021; 100% subsidiary of listed Gujarat Fluorochemicals (GFL), part of the INOXGFL Group. A vertically integrated maker of intermediate materials for lithium-ion and sodium-ion batteries.
• Product suite covers ~50% of the Li-ion battery value chain: electrolyte salts (LiPF6, NaPF6), additives and formulations; LFP cathode active material (CAM); and binders (PVDF, PTFE). Battery-chemistry agnostic.
• Building an integrated complex at Jolva, Gujarat, co-located with GFL's fluorochemicals facility for raw-material and cost synergies. Targeting India, USA and EU; 20+ customer engagements in the pipeline.

The catalyst

• Large, fast-growing addressable markets: India EV battery demand ~17.7 GWh (2025) to ~256 GWh (2032) at ~35% CAGR; battery materials USD 1.05 bn (2025) to USD 2.03 bn (2030); Li-ion batteries USD 5.78 bn to USD 16.09 bn (2030, ~22.7% CAGR).
• High-value chemistry: the opportunity sits in electrolytes (e.g., LiPF6) and binders (PVDF) - exactly where GFCL EV plays, with a portfolio capturing ~35% of battery value.
• Strategic push to de-risk supply chains away from China; parent GFL's deep fluorine-chemistry expertise and backward integration, with management guiding for a minimum ~2x asset turnover.

The financials

Still in the build-and-qualify phase, as expected for battery chemicals. Revenue is small but scaling — ₹0.37 cr (FY24) to ₹9.44 cr (FY25) to ₹33.22 cr (FY26) — while losses widen as the Jolva complex and capex build out (FY26 PAT −₹104 cr, finance cost ~₹17 cr). This is the normal shape of a long-gestation materials business: R&D, then testing, then OEM qualification, then mass production. Source: UnlistedZone P&L (converted from ₹ lakh).

The backers

• Backed by GFL/INOXGFL with proven specialty-chemicals execution and capital; GFL has itself infused several hundred crore into the subsidiary.
• Raised ~Rs 800 cr equity with marquee family offices on board - Sunil Bharti Mittal, Varun Beverages, RPSG Group, Manyavar and Dalmia - alongside a Rs 6,000-8,100 cr capex plan running to FY28.

The valuation

• Live price ₹40; market cap ~₹29,548 cr against FY26 revenue of ~₹33 cr and a ~₹104 cr loss — the valuation is an option on the future battery-materials ramp, not current financials.
• Crucially, this is a long-gestation business: battery chemistry has to be developed (R&D), then internally tested, then qualified by OEMs over long cycles, and only then does mass production and revenue follow. Early losses and heavy capex are the expected shape of that journey, not a warning sign.
• Funding is advancing (₹800 cr equity raised, marquee family offices in; ₹6,000–8,100 cr capex plan), and GFCL EV's portfolio captures ~35% of battery value. The bet is on the Jolva complex, OEM qualification and non-China demand landing — high reward if it does, but with the long lead times and rich valuation as the key risks.

The business

• Owns the Chennai Super Kings IPL franchise (est. 2014; five IPL titles, a record run of playoff appearances). One of the few sports franchises retail investors can own pre-listing.
• Revenue streams: central media-rights pool (the largest), sponsorships, gate receipts, merchandise, prize money and academy/digital income.
• Diversifying beyond the two-month IPL window via overseas franchises - Joburg Super Kings (SA20) and Texas Super Kings (Major League Cricket) - plus Super Kings cricket academies.

The catalyst

• The 2023-27 IPL media-rights deal (~Rs 50,000 cr) splits ~50% to franchises, giving each team a stable ~Rs 500 cr/yr central inflow.
• Secular rise of the IPL's viewership and commercial clout; soaring franchise valuations (e.g., peer benchmarks at $1-2 bn).
• Powerful, durable brand and fan loyalty ('Yellow Army', MS Dhoni) underpinning sponsorship and merchandise pricing power.

The financials

FY24 was a bumper year (+131% revenue) on the new media-rights pool; FY25 softened after a last-place finish cut prize money — illustrating the earnings cyclicality with on-field performance. Figures indicative.

The backers

• Led by MD K S Viswanathan; mature, well-run franchise with a long operating track record.
• Strategic global expansion (SA20, MLC) to build year-round revenue and brand reach.

The valuation

• The valuation case is relative. In early 2026, RCB sold at ~₹16,660 cr ($1.78 bn) and Rajasthan Royals at ~₹16,290 cr ($1.63 bn); Gujarat Titans' 67% stake implied ~₹7,500 cr.
• Against those transacted benchmarks, CSK — the most decorated and one of the most valuable IPL brands — at ~₹9,800 cr looks comparatively cheap, especially given it is profitable and trades below the RCB/RR marks despite arguably a stronger franchise.
• Caveat: those are control-stake private deals (which carry a premium) versus a minority unlisted share; earnings still swing with on-field results and there's no confirmed IPO.

The business

• Founded 1995 (as Mass Kinematics); a leading Indian advanced-composites manufacturer with three Goa facilities (~33,000 sq m, 400+ employees) and in-house design-to-serial-production capability.
• Segments: Defence (India's first indigenous sonar dome, carbon-fibre rapid-deployable bridges, radomes), Aerospace (structural parts for aircraft, helicopters, UAVs, spacecraft), Railways (Vande Bharat / coach interiors, cab modules) and Industrial (pressure vessels).
• Aerospace & Defence SBU via Kineco Kaman Composites India (KKCI) - a 2012 JV with Kaman Aerospace (USA), taken to 100% ownership in 2024-25. NADCAP / AS9100 accredited.

The catalyst

• Defence indigenisation and aerospace localisation; Airbus/Boeing Tier-1 suppliers increasingly sourcing from India.
• Space program tailwind - delivered components for Chandrayaan-3 and Gaganyaan; growing ISRO/HAL programs (LCA, ALH).
• Rail modernisation (Vande Bharat) provides steady cash-flow ballast; March-2025 multi-million-dollar GKN Aerospace contract for business-jet composites.

The financials

FY23 was a loss year (PAT −₹8.5 cr) before a clean turnaround: revenue grew to ₹245 cr (FY25, +40% YoY) with EBITDA margin lifting to ~16.7% and PAT recovering to ₹13 cr. Finance cost eased (₹12 cr → ₹8 cr) after the equity infusion. Source: UnlistedZone P&L.

The backers

• Founder-promoter Shekhar Sardessai retains majority control; 25+ year domain track record.
• Brought KKCI fully in-house (2024-25) to capture aerospace value; equity infusion (~Rs 88 cr) cut debt and lifted interest coverage from ~0.7x (FY23) to ~2.2x (FY24).
• Recent fundraise: a series of equity allotments across Nov-Dec 2025 (~Rs 80 cr total) at Rs 3,006/share (Rs 10 face value + Rs 2,996 premium), funding the growth plan.

The valuation

• A useful valuation anchor: Kineco's most recent capital raise (a series of allotments across Nov–Dec 2025, ~₹80 cr in total) was done at ₹3,006/share (₹10 face value + ₹2,996 premium). The unlisted stock trades at ~₹3,285 today — only a modest premium to that fresh-issue price.
• On FY25 EPS of ~₹18 the trailing P/E is high (~180x), so the case rests on the turnaround continuing — defence/aerospace order ramp lifting both growth and margins from the FY25 base.
• For a niche, high-barrier composites business with global aerospace accreditations and ISRO/HAL programs, the entry near the recent allotment price looks reasonable, but the multiple needs the growth to keep delivering.

The business

• Incorporated 2012; a structural-steel manufacturer headquartered in Bhilai, Chhattisgarh, strategically located near the Bhilai Steel Plant for efficient raw-material access and distribution.
• Produces angles, channels, flats and rods used in power-transmission lines, bridges, buildings and transport infrastructure. Notably the only steel mill in the region approved by PowerGrid.
• Key clients include PowerGrid, Indian Railways and Kalpataru Power; progressing a merger of its engineering unit with the core structural-steel business to unlock synergies.

The catalyst

• India's infrastructure, power-transmission and construction capex cycle drives structural-steel demand.
• Exclusive PowerGrid approval in the region is a meaningful qualification advantage for transmission projects.
• Cost-efficient location near Bhilai supports competitive supply across western, northern and central India.

The financials

Strong topline growth — revenue ₹193 cr → ₹340 cr (FY25, +42% YoY) with PAT rising to ₹18.5 cr and OPM steady ~10%. EPS fell to ₹12.42 (from ₹18.15) despite higher PAT — the fresh share issue plus a 1:1 bonus expanded the share count. Leverage is rising: borrowings grew ₹30 cr → ₹58 cr → ₹84 cr and total assets reached ₹241 cr (FY25), driven largely by inventory (₹150 cr) and receivables (₹42 cr). A cyclical, working-capital-heavy commodity business. Source: UnlistedZone P&L / balance sheet.

The backers

• Led by MD Jayant Agrawal (Agrawal family promoters).
• Raised ~Rs 36 cr by issuing 18 lakh shares at Rs 200 for expansion and working capital; pre-IPO backers include Planify Capital and VPK Global Ventures. This was followed by a 1:1 bonus issue, doubling the share count.
• CRISIL rating upgraded from BBB- to BBB (Infomerics aligned) - reflecting a strengthened financial position.

The valuation

• On FY25 earnings the stock trades at ~19x P/E and ~3.35x P/B with a ~19.5% ROE — a reasonable, not-stretched multiple for a steel SME, reflecting the cyclical nature of the business.
• Recently raised ~₹36 cr issuing 18 lakh shares at ₹200 (backers include Planify Capital and VPK Global Ventures), followed by a 1:1 bonus; the unlisted price now sits at ~₹118 (near its 52-week low), reflecting the steel cycle and the larger share base.
• Topline grew well (+42% in FY25) and PAT hit ₹18.5 cr, but borrowings have climbed to ~₹84 cr and the balance sheet is working-capital-heavy — so the PowerGrid approval and new capacity have to keep earning to justify the leverage. A cyclical, IPO-expectation-driven bet.

The business

• Originally Maveric Solution Inc (3D scanning, reverse engineering, prototyping); pivoted to healthcare simulation in 2019, introducing the Anatomage virtual dissection table in India.
• B2B, solution-led model: designs and sells 40+ hardware simulators across fidelity levels (AI/AR/VR-enabled patient, surgical and task trainers), plus simulation software and training/curriculum services.
• Builds entire turnkey simulation labs (not just equipment), with hybrid pricing from ~Rs 2,500 to ~Rs 5 cr; many products manufactured in India.

The catalyst

• Rising demand for simulation-based medical training that avoids practising on real patients; growth in medical and nursing education.
• Targets Tier-I medical colleges and Tier-II/III nursing institutes - large under-penetrated market with import-substitution upside.
• SaaS-based simulation software and turnkey labs widen the addressable base and add recurring revenue.

The financials

An explosive FY25: revenue jumped from ₹14.2 cr to ₹136.3 cr (~10x) and PAT from ₹0.94 cr to ₹47.8 cr, with EBITDA margin vaulting to ~45% and EPS to ₹97.35. The company was only reconstituted as a limited entity recently, so the public series is short (FY24–FY25). Such a sharp jump is impressive but worth scrutinising for sustainability and cash conversion. Source: UnlistedZone P&L.

The backers

• Founded by Anuj Chahal (Founder & MD) and Kanika Chahal (Co-founder & Director); experienced cross-functional team (engineering + medical + business), 50+ experts.
• Domestic R&D and manufacturing in New Delhi with global technology collaborations.

The valuation

• A standout FY25 — revenue ~10x to ₹136 cr, PAT ₹47.8 cr, ~45% EBITDA margin and EPS ₹97.35. Against the ₹2,275 price that's a trailing P/E of only ~23x, which looks cheap for that growth rate.
• The catch is durability: a one-year ~10x jump in a lumpy, project/tender-led business needs to prove it can repeat. Innovations Venture Studio (12.5% stake) and a ₹50 cr R&D commitment support the scale-up story.
• Watch cash conversion and receivables against institutional/government procurement cycles; public disclosure is thin and the unlisted stock is illiquid — so the low headline multiple comes with real uncertainty.